David Heredia: EGFRm NSCLC to SCLC Transformation – A Therapeutic Dead Zone
David Heredia, Head of Oncology Department at Punta Médica Hospital, shared a post on X:
“EGFRm NSCLC → SCLC transformation: still a therapeutic dead zone
Post-transformation treatment outcomes:
- ORR: 25%
- mPFS: 3.4 mo
- mOS: 9.9 mo
SCLC switch = poor prognosis despite platinum-etoposide. Need for better biomarkers and tailored therapies.”
Title: Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study
Authors: C. Catania, S.V. Liu, M. Garassino, A. Delmonte, V. Scotti, F. Cappuzzo, C. Genova, A. Russo, M. Russano, C. Bennati, I. Colantonio, S. Martini, M. Pino, F. Conforti, L. Pala, G. Muti, F. Citarella, E. Olmetto, A. Esposito, P. Cascetta, A. Di Lello, T. De Pas
You can read the Full Article on ESMO Open
More posts featuring David Heredia.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023